FDA Pushes Psychedelic-Inspired Treatment for Postpartum Depression
Big news out of the Reunion Neuroscience camp!
The New Jersey-based biotech announced that the FDA has officially granted Breakthrough Therapy Designation to luvesilocin (RE104). This is the company’s novel compound designed to treat postpartum depression (PPD).
Postpartum depression is one of the most common complications of childbirth worldwide. Globally, it affects an estimated 10% of women after childbirth. With roughly 130 million births globally each year, that translates to approximately 13 million mothers annually experiencing significant depressive symptoms during the postpartum period. Rates can be even higher in low- and middle-income countries, where access to mental health care is limited and social stressors are greater.
So indeed, the FDA’s decision is welcome news.
If you’re unfamiliar, luvesilocin is a proprietary prodrug of a psychedelic-inspired molecule in the tryptamine family, designed to deliver rapid mood-elevating effects with a short psychoactive experience via a single subcutaneous injection.
Unlike traditional antidepressants that can take weeks to work, RE104 has shown rapid, durable effects in clinical testing, with significant reductions in depressive symptoms beginning as early as Day 1 and maintained through Day 28 in a Phase 2 trial.
In that study, 70% of participants receiving the therapeutic dose reached remission at both Week 1 and Week 4, a result that is both clinically meaningful and unprecedented in many existing treatment options.
Reunion Neuroscience now plans to initiate a pivotal Phase 3 trial in PPD.
Beyond postpartum depression, RE104 is also being evaluated for other conditions, including adjustment disorder and generalized anxiety disorder.
Also worth reading …
Reunion’s psychedelic prodrug reduces postpartum depression symptoms in phase 2 study: https://www.fiercebiotech.com/biotech/reunions-psychedelic-prodrug-reduces-post-partum-depression-phase-2-study
Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring: https://www.nature.com/articles/s41467-025-64371-5
Department of Defense funds UT clinical trial of drug-free postpartum depression treatment: https://dellmed.utexas.edu/news/department-of-defense-funds-ut-clinical-trial-of-drug-free-postpartum-depression-treatment